Tags

Type your tag names separated by a space and hit enter

HIV virological suppression influences response to the AS03-adjuvanted monovalent pandemic influenza A H1N1 vaccine in HIV-infected children.
Influenza Other Respir Viruses. 2014 May; 8(3):360-6.IO

Abstract

DESIGN

Children with HIV are especially susceptible to complications from influenza infection, and effective vaccines are central to reducing disease burden in this population. We undertook a prospective, observational study to investigate the safety and immunogenicity of the inactivated split-virion AS03-adjuvanted pandemic H1N1(2009) vaccine in children with HIV.

SETTING

National referral centre for Paediatric HIV in Ireland.

SAMPLE

Twenty four children with HIV were recruited consecutively and received two doses of the vaccine. The serological response was measured before each vaccine dose (Day 0 and Day 28) and 2 months after the booster dose. Antibody titres were measured using a haemagglutination inhibition (HAI) assay. Seroprotection was defined as a HAI titre ≥ 1:40; seroconversion was defined as a ≥ fourfold increase in antibody titre and a postvaccination titre ≥ 1:40.

MAIN OUTCOME MEASURES

The seroconversion rates after prime and booster doses were 75% and 71%, respectively. HIV virological suppression at the time of immunization was associated with a significantly increased seroconversion rate (P = 0·009), magnitude of serological response (P = 0·02) and presence of seroprotective HAI titres (P = 0·017) two months after the booster dose. No other factor was significantly associated with the seroconversion/seroprotection rate. No serious adverse effects were reported. Vaccination had no impact on HIV disease progression. The AS03-adjuvanted pandemic H1N1 vaccine appears to be safe and immunogenic among HIV-infected children. A robust serological response appears to be optimized by adherence to a HAART regimen delivering virological suppression.

Authors+Show Affiliations

Department of Paediatric Infectious Diseases and Immunology, Our Lady's Children's Hospital, Dublin, Ireland.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Observational Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24548473

Citation

Leahy, Timothy R., et al. "HIV Virological Suppression Influences Response to the AS03-adjuvanted Monovalent Pandemic Influenza a H1N1 Vaccine in HIV-infected Children." Influenza and Other Respiratory Viruses, vol. 8, no. 3, 2014, pp. 360-6.
Leahy TR, Goode M, Lynam P, et al. HIV virological suppression influences response to the AS03-adjuvanted monovalent pandemic influenza A H1N1 vaccine in HIV-infected children. Influenza Other Respir Viruses. 2014;8(3):360-6.
Leahy, T. R., Goode, M., Lynam, P., Gavin, P. J., & Butler, K. M. (2014). HIV virological suppression influences response to the AS03-adjuvanted monovalent pandemic influenza A H1N1 vaccine in HIV-infected children. Influenza and Other Respiratory Viruses, 8(3), 360-6. https://doi.org/10.1111/irv.12243
Leahy TR, et al. HIV Virological Suppression Influences Response to the AS03-adjuvanted Monovalent Pandemic Influenza a H1N1 Vaccine in HIV-infected Children. Influenza Other Respir Viruses. 2014;8(3):360-6. PubMed PMID: 24548473.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - HIV virological suppression influences response to the AS03-adjuvanted monovalent pandemic influenza A H1N1 vaccine in HIV-infected children. AU - Leahy,Timothy R, AU - Goode,Michelle, AU - Lynam,Paul, AU - Gavin,Patrick J, AU - Butler,Karina M, Y1 - 2014/02/18/ PY - 2014/01/13/accepted PY - 2014/2/20/entrez PY - 2014/2/20/pubmed PY - 2014/12/15/medline KW - AS03 adjuvant KW - HIV KW - pandemic H1N1 influenza KW - vaccination SP - 360 EP - 6 JF - Influenza and other respiratory viruses JO - Influenza Other Respir Viruses VL - 8 IS - 3 N2 - DESIGN: Children with HIV are especially susceptible to complications from influenza infection, and effective vaccines are central to reducing disease burden in this population. We undertook a prospective, observational study to investigate the safety and immunogenicity of the inactivated split-virion AS03-adjuvanted pandemic H1N1(2009) vaccine in children with HIV. SETTING: National referral centre for Paediatric HIV in Ireland. SAMPLE: Twenty four children with HIV were recruited consecutively and received two doses of the vaccine. The serological response was measured before each vaccine dose (Day 0 and Day 28) and 2 months after the booster dose. Antibody titres were measured using a haemagglutination inhibition (HAI) assay. Seroprotection was defined as a HAI titre ≥ 1:40; seroconversion was defined as a ≥ fourfold increase in antibody titre and a postvaccination titre ≥ 1:40. MAIN OUTCOME MEASURES: The seroconversion rates after prime and booster doses were 75% and 71%, respectively. HIV virological suppression at the time of immunization was associated with a significantly increased seroconversion rate (P = 0·009), magnitude of serological response (P = 0·02) and presence of seroprotective HAI titres (P = 0·017) two months after the booster dose. No other factor was significantly associated with the seroconversion/seroprotection rate. No serious adverse effects were reported. Vaccination had no impact on HIV disease progression. The AS03-adjuvanted pandemic H1N1 vaccine appears to be safe and immunogenic among HIV-infected children. A robust serological response appears to be optimized by adherence to a HAART regimen delivering virological suppression. SN - 1750-2659 UR - https://www.unboundmedicine.com/medline/citation/24548473/HIV_virological_suppression_influences_response_to_the_AS03_adjuvanted_monovalent_pandemic_influenza_A_H1N1_vaccine_in_HIV_infected_children_ L2 - https://doi.org/10.1111/irv.12243 DB - PRIME DP - Unbound Medicine ER -